Edition:
India

Aurinia Pharmaceuticals Inc (AUP.TO)

AUP.TO on Toronto Stock Exchange

6.19CAD
18 Oct 2019
Change (% chg)

$-0.12 (-1.90%)
Prev Close
$6.31
Open
$6.25
Day's High
$6.58
Day's Low
$6.09
Volume
47,182
Avg. Vol
37,500
52-wk High
$10.47
52-wk Low
$4.70

Latest Key Developments (Source: Significant Developments)

Aurinia Reports Last Patient Study Visit In Aurora Phase 3 Lupus Nephritis Study And Provides Update On ATM Facility
Wednesday, 16 Oct 2019 

Oct 16 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA REPORTS LAST PATIENT STUDY VISIT IN AURORA PHASE 3 LUPUS NEPHRITIS STUDY AND PROVIDES UPDATE ON ATM FACILITY.AURINIA PHARMACEUTICALS - AURORA PHASE 3 RESULTS WITH VOCLOSPORIN FOR TREATMENT OF LUPUS NEPHRITIS REMAIN ON TRACK TO BE REPORTED BY END OF Q4 2019.AURINIA PHARMACEUTICALS INC - CO DOES NOT INTEND TO CONDUCT FURTHER SALES PURSUANT TO ATM AT THIS TIME.  Full Article

Aurinia Reports Q2 2019 Results
Wednesday, 7 Aug 2019 

Aug 6 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.AURINIA PHARMACEUTICALS INC - INITIATING AUDREY™ PHASE 2/3 CLINICAL STUDY FOR VOS IN DRY EYE SYNDROME.AURINIA PHARMACEUTICALS INC - FULLY-ENROLLED AURORA PHASE 3 TRIAL IN LUPUS NEPHRITIS CONTINUES ON TRACK WITH RESULTS ANTICIPATED IN LATE 2019.AURINIA PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.17.  Full Article

Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Superior Efficacy In A Phase 2 Head-To-Head Study
Tuesday, 22 Jan 2019 

Jan 22 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA ANNOUNCES VOCLOSPORIN OPHTHALMIC SOLUTION DEMONSTRATES STATISTICALLY SUPERIOR EFFICACY VERSUS RESTASIS® IN A PHASE 2 HEAD-TO-HEAD STUDY FOR THE TREATMENT OF DRY EYE SYNDROME.AURINIA PHARMACEUTICALS INC - PRIMARY ENDPOINT OF DROP DISCOMFORT AT 1-MINUTE ON DAY 1 SHOWED NO STATISTICAL DIFFERENCE BETWEEN VOS AND RESTASIS.AURINIA PHARMACEUTICALS INC - NO SERIOUS ADVERSE EVENTS WERE REPORTED IN STUDY, AND THERE WERE NO UNEXPECTED SAFETY SIGNALS..  Full Article

Aurinia Pharmaceuticals Reports Qtrly Loss Per Share ‍of $0.04​
Friday, 16 Mar 2018 

March 15 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.AURINIA PHARMACEUTICALS INC QTRLY LOSS PER SHARE ‍$0.04​.AURINIA PHARMACEUTICALS INC - ‍TRIALS IN FSGS AND DRY EYE TO BEGIN IN Q2 2018​.  Full Article

Aurinia reports Q3 loss per share $0.16
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Aurinia Pharmaceuticals Inc :Aurinia reports third quarter 2017 financial results and provides operational highlights.Aurinia Pharmaceuticals Inc - ‍Aurora phase III trial in lupus nephritis on track​.Q3 loss per share $0.16.Aurinia Pharmaceuticals - Believe​ co have sufficient financial resources to fund LN program,conduct work on new indications & fund operations into 2020.  Full Article